A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA
Interim results of SOTERIA support the favourable benefit-risk of add-on sotatercept treatment in adults with PAH. Follow-up reports from this study will provide additional information on benefit-risk.
Authors
- Janethe de Oliveira Pena (ORCID: https://orcid.org/0009-0002-8735-4698)
- Ioana R. Preston (ORCID: https://orcid.org/0000-0002-1378-7362)
- Marius M. Hoeper (ORCID: https://orcid.org/0000-0001-9086-2293)
- Aaron B. Waxman (ORCID: https://orcid.org/0000-0001-7797-0361)
- Solaiappan Manimaran (ORCID: https://orcid.org/0000-0001-8485-780X)
- J. Simon R. Gibbs (ORCID: https://orcid.org/0000-0001-6147-9252)
- Mardi Gomberg‐Maitland (ORCID: https://orcid.org/0000-0003-0482-4560)
- David B. Badesch
- Vallerie V. McLaughlin (ORCID: https://orcid.org/0000-0002-8907-1651)
- Marc Humbert (ORCID: https://orcid.org/0000-0003-0703-2892)
- Hossein Ardeschir Ghofrani (ORCID: https://orcid.org/0000-0002-2029-4419)
- Anna Lau (ORCID: https://orcid.org/0000-0002-1546-7004)
- Rogério Souza (ORCID: https://orcid.org/0000-0003-2789-9143)
- Madhavi Reddy (ORCID: https://orcid.org/0000-0001-6078-3789)
- Elina Mikhailova
Institutions
- Brigham and Women's Hospital (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Colorado Hospital (US)
- Tufts Medical Center (US)
- Inserm (FR)
- George Washington University (US)
- Justus-Liebig-Universität Gießen (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- Université Paris-Saclay (FR)
- University of Michigan (US)
- Medizinische Hochschule Hannover (DE)
- MSD (UK) Limited (United Kingdom) (GB)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- Bicêtre Hospital (FR)
- Imperial College London (GB)
- University of Colorado Denver (US)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1183/13993003.01435-2024
- Citations
- 32
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 48.59
Funders
- Merck